| References |
Top |
| REF 1 |
Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science. 1993 Nov 5;262(5135):900-2.
|
| REF 2 |
Bikunin down-regulates heterodimerization between CD44 and growth factor receptors and subsequently suppresses agonist-mediated signaling. J Cell Biochem. 2005 Apr 1;94(5):995-1009.
|
| REF 3 |
Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J. 2001 Feb 1;20(3):480-90.
|
| REF 4 |
A widely expressed transmembrane serine/threonine kinase that does not bind activin, inhibin, transforming growth factor beta, or bone morphogenic ... J Biol Chem. 1993 Jun 15;268(17):12719-23.
|
| REF 5 |
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000 Jan 15;14(2):163-76.
|
| REF 6 |
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network. J Proteome Res. 2014 Dec 5;13(12):5339-46.
|
| REF 7 |
Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in -Catenin-Active Cancers. Cell Syst. 2016 Sep 28;3(3):302-316.e4.
|
| REF 8 |
A human MAP kinase interactome. Nat Methods. 2010 Oct;7(10):801-5.
|
